Further, the expression of the alternative ligand IL-34 is organ specific and carcinoma cells produce significant amounts of CSF-1 as well as IL-34, which partially interferes with the anti-CSF-1 treatment effects. This evidence concerns the gene CSF1 and carcinoma.